๐ Weekly Report May 18, 2026 (PDF) โ Download
๐ Podcast May 18, 2026 (MP3) โ Play & Download
iPS Cells & Regenerative Medicine Weekly Report May 18, 2026
- Lonza Reports Strong Q1 2026 Performance, Driven by Robust CDMO Growth and Strategic Transformation into Pure-Play Biopharma Partner
- Hydrogen Energy Weekly Report May 18, 2026
Author of this article
้ข้ฃ่จไบ
-
iPS Cells & Regenerative Medicine Weekly Report August 9, 2026 -
Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPEโข Platform Enables Scalable Manufacturing
-
CAR-T Cell Therapy Established for Specific B-Cell Lymphomas/Leukemias, but Product Differentiation and Individualized Adaptation Crucial
-
Cell Therapy Clinical Success Hinges on Manufacturability: Limitations of Autologous Therapies Drive Interest in Allogeneic ‘Off-the-Shelf’ Platforms
-
EVERSANA Selected as Commercialization Partner for Innovacell Inc.’s Novel Cell Therapy ICEF15 for Urgent Fecal Incontinence in the United States
-
China’s First Approved MSC Therapy, Ruibosheng, Launched at Fraction of Global Price, Receives Conditional Approval for Severe GVHD
-
Fate Therapeutics Executives Sell Shares Post-FDA IND Approval for Next-Gen Autoimmune CAR-T Candidate FT839, Market Anticipates Basket Trial Success
-
Real-World Data Evaluates Incidence and Management of Cytokine Release Syndrome and Neurotoxicity Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel CAR-T Cell Therapy Across 87 U.S. Centers
Comments